This is a very exciting moment for the Santen US affiliate
In Conversation
With rare disease patients and families deeply affected by COVID-19, important policy issues at a critical point and scientific innovation advancing more rapidly than at any…
Across research, development, and commercialization, our team is focused on advancing innovations that can address unmet needs, and we expect to see huge growth despite the…
We need to try and make sure that we are following the science [on COVID-19 vaccines] very closely, and refrain from getting lost in all the…
From my experience, many great ideas actually come from people unconstrained by the conventions and cultural uniformities of large organisations
We have learned that to perform well in the US, we need to have a consistently robust pipeline instead of relying on just one or two…
Whether there is a pandemic or not, brain diseases don’t stop
At Novartis, we do not shy away from competition. It is a good thing and it demonstrates the attractiveness of the market. There is a reason…
The key priority for my tenure is to create sustainability, both for Amgen and for biosimilars more generally within the global market.
The most important element of any drug is whether it has a meaningful impact on patient outcomes. If you get that right, everything else takes care…
We have many programs currently in Phase III development. All these medicines are potentially transformative in nature. These are not ‘me too’ drugs that aim to…
My priority leading LEO Pharma Inc. in the US is attracting, developing and retaining members of our team. We have focused on building a company culture…
